Merck’s SC Pembrolizumab Shows Noninferior PK to IV KEYTRUDA in Trial Merck, known as MSD outside of the United States and Canada, has presented the first data from the pivotal 3475A-D77 Phase 3 trial evaluating subcutaneous pembrolizumab in combination with…
Novotech Report Highlights Surge in siRNA Research with 150+ Clinical Trials (2020-2024) Novotech, a globally recognized full-service clinical research organization (CRO) and scientific advisory company, has released its latest preclinical report exploring the rapidly evolving landscape of small interfering RNA…
Blue Lake Biotechnology’s Intranasal COVID-19 Vaccine Candidate Demonstrates Long-Lasting Immunity and Broad Protection Blue Lake Biotechnology, Inc., a clinical-stage biotechnology company specializing in intranasal vaccine development, along with its affiliate CyanVac LLC, recently published two pivotal preclinical studies in the…
Epicrispr Biotech Raises $68M for FSHD Epigenetic Therapy Trial Epicrispr Biotechnologies, a pioneering biotechnology company dedicated to developing curative therapies, has announced the successful first close of its Series B financing, securing $68 million. The funds will be used to…
CEL-SCI: Multikine Boosts Quality of Life by Up to 95% in Head & Neck Cancer Patients CEL-SCI Corporation (NYSE American: CVM) has recently announced the publication of new data from its Phase 3 study of Multikine* (Leukocyte Interleukin, Injection) in…
SCORPIO-PEP Phase 3: Ensitrelvir First Oral Antiviral to Prevent COVID-19 Post-Exposure Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) presented late-breaking scientific findings at the Conference of Retroviruses and Opportunistic Infections (CROI)…
City of Hope’s Phase 1 Trial Featured at SSO Annual Meeting City of Hope’s groundbreaking Phase 1 clinical trial has demonstrated promising results for patients suffering from colorectal and appendiceal cancer that has metastasized to the peritoneum. As one of…
Seismic Therapeutic Starts Phase 1 Trial of S-1117 for Antibody-Mediated Diseases Seismic Therapeutic, Inc., a machine learning-driven immunology company, has announced a significant milestone in its journey toward developing transformative therapies for autoimmune diseases. The company has dosed the first…
Care Access Acquires Brazil-Based Clinical Research Center CEMEC Care Access, a globally recognized healthcare and clinical research organization, has announced the successful acquisition of Centro Multidisciplinar de Estudos Clínicos (CEMEC), a leading clinical research center based in Brazil. This acquisition…
NeoGenomics Acquires Pathline to Strengthen Oncology Testing in the Northeast NeoGenomics, Inc. (“NeoGenomics” or the “Company”) (NASDAQ:NEO), a leading provider of oncology testing services, has announced its acquisition of Pathline, LLC, a CLIA/CAP/NYS-certified laboratory based in New Jersey. This acquisition…
Agomab Announces Positive Topline Phase 2a Interim Results for AGMB-129 in Fibrostenosing Crohn’s Disease Agomab Therapeutics NV (“Agomab”), a biotechnology company focused on developing innovative treatments for fibrotic diseases, has announced positive interim results from its ongoing STENOVA Phase 2a…
Virpax Explores MET Technology for Intranasal COVID-19 Vaccine Development Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) (“Virpax” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative, non-addictive treatments for pain management, central nervous system (CNS) disorders, post-traumatic stress disorder, and…